'Spiders' that battle cancer

April 29, 2014, Montana State University

It is rare that one can find a person whose life has not been impacted by cancer, whether it be in a loved one, friend or acquaintance. At MSU, scientists are contributing in major ways to science to combat the disease that kills 1,500 people each day in the U.S., according the American Cancer Society. Mary Cloninger, a prize-winning organic chemistry professor at MSU, explains molecules that look like spiders, how cells "talk" to each other, and her laboratory's work to better understand the malfunctions that cause cancer to grow.

What specifically is your research group doing in the battle against cancer?

One of the early steps in cancer is that similar cells clump together—they aggregate. In addition to aggregating, these cells are multiplying and basically becoming a tumor. In my research group, we study the processes that cause to form clumps because these processes are important for tumor formation and for .

I think that's something that many people don't realize: cancer cells don't invade us, they're not viruses or bacteria that we get from the environment. Cancer cells are our cells but something has gone haywire with them so they aggregate and then start to replicate themselves as if their reproducing or cell-dividing "off switches" were broken.

By studying the process in which cells aggregate and looking at ways we might be able to disrupt that process, we hope to find a way to deal with cancers at a very early stage. In addition, if we can figure out how to make cancer cells unclump—or disaggregate—that could have implications for late-stage cancers, too.

How are you trying to make cancer cells 'unclump'?

To study cancer cell behaviors, we make large molecules called dendrimers. The dendrimers have many arms that branch out from a core, kind of like a many-armed spider. At the outside edges of the arms (where your hands are), we can decorate the dendrimers with groups that bind well to proteins that surround cancer cells. When we send the dendrimers into the cellular environment, we evaluate whether the presence of the dendrimer can change the cell's behavior. Think of the dendrimer as a wrench that we're throwing into a cancer engine. By seeing what stops working and what keeps working, or works in different ways, we can learn a lot about how the cell processes work. The more we are able to learn about how the cell functions, the more likely it is that we will be able to restore healthy processes if and when things go wrong in diseases such as cancer.

Making these dendrimers is not an easy task. If I go back to the image of a spider with many arms, my students and I tailor the size of the spider's body, the number of arms that the spiders have, and the number and type of carbohydrates that we put where the spider's arms (feet?) should be. We spend a lot of time synthesizing compounds in flasks in the lab and then purifying and characterizing them to make sure that we know exactly what we have. Then we develop the protocols for how to study the dendrimers' effect on the cancer cells. Sometimes, for example, we make dendrimers that give off a green fluorescent glow so that we can track them while they're interacting with the cells. We all like to work with the green dendrimers!

How do cells communicate with one another and with their surroundings?

Cells use the carbohydrates that coat their surfaces as one important way to communicate with their surroundings. Carbohydrates are big groups of simple sugars such as the lactose that you find in milk and the glucose that you need for energy pathways in your body. In food, carbohydrates make up starches and dietary fiber. On the surface of a healthy cell, carbohydrates are there to help the cells to perform many important tasks including mounting an immune response against invaders, differentiating during growth ("deciding" what kind of cell it is going to be), and initiating uptake of hormones and cell signaling proteins. Cancer cells have different carbohydrates on their surfaces than , and the cancer cell carbohydrates can bind to proteins that enable them to aggregate and form tumors, for example.

Our dendrimers are designed to intercept the cancer cellular aggregation/tumor formation process. We have incorporated carbohydrates onto the dendrimers' surface that bind well to proteins that cause the cells to aggregate. When the dendrimers bind to the protein, then the protein isn't able to bind normally to the cells. The dendrimer diverts the main players in the cancer cell aggregation process (the cells and some of the proteins that surround them) from their normal purpose of . Thoughtful design of the allows us to make molecules that can either make cancer cells stickier or less sticky. This teaches us about possible ways that new therapeutic agents can be designed that may one day help doctors to fight tumor growth and cancer metastasis.

Explore further: Researchers identify 'carbohydrates in a coal mine' for cancer detection

Related Stories

Researchers identify 'carbohydrates in a coal mine' for cancer detection

March 3, 2014
Researchers at New York University and the University of Texas at Austin have discovered that carbohydrates serve as identifiers for cancer cells. Their findings, which appear in the journal Proceedings of the National Academy ...

Team discovers new mechanism allowing tumor cells to escape immune surve

March 18, 2014
The immune system plays a pivotal role in targeting cancer cells for destruction. However, tumor cells are smart and have developed ways to avoid immune detection. A collaborative team of researchers at Moffitt Cancer Center ...

One cell type may quash tumor vaccines

April 28, 2014
Most cancer vaccines have not lived up to their promise in clinical trials. The reason, many researchers suspect, is that the immune cells that would help the body destroy the tumor – even those reactions boosted by cancer ...

Researchers discover disruptions in signaling pathways that enable colorectal cancer cells to form metastases

March 24, 2014
Researchers at the University of Freiburg have found switches that colorectal cancer cells use to migrate away from the primary tumor site and to invade neighboring tissue. This migration is the first step in metastasis, ...

Breast cancer cell subpopulation cooperation can spur tumor growth

April 8, 2014
Subpopulations of breast cancer cells sometimes cooperate to aid tumor growth, according to Penn State College of Medicine researchers, who believe that understanding the relationship between cancer subpopulations could lead ...

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.